BICO Group 将来の成長

Future 基準チェック /36

BICO Group利益と収益がそれぞれ年間130.3%と8.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に1.4% 130.3%なると予測されています。

主要情報

130.3%

収益成長率

130.3%

EPS成長率

Life Sciences 収益成長	18.4%
収益成長率	8.3%
将来の株主資本利益率	1.4%
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

OTCPK:CLLK.F - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,925	100	N/A	N/A	1
12/31/2025	2,618	-27	-38	146	2
12/31/2024	2,299	-177	-420	-142	2
6/30/2024	2,423	-1,498	-35	98	N/A
3/31/2024	2,426	-1,649	-98	101	N/A
12/31/2023	2,405	-1,697	-113	178	N/A
9/30/2023	2,252	-527	-436	-53	N/A
6/30/2023	2,256	-390	-527	-72	N/A
3/31/2023	2,297	-117	-643	-140	N/A
12/31/2022	2,327	-85	-799	-269	N/A
9/30/2022	2,278	41	-817	-313	N/A
6/30/2022	1,995	-130	-872	-457	N/A
3/31/2022	1,743	-224	-816	-462	N/A
12/31/2021	1,378	-228	-676	-409	N/A
9/30/2021	993	-188	-529	-321	N/A
6/30/2021	744	-96	-328	-150	N/A
3/31/2021	460	-50	-156	-34	N/A
12/31/2020	369	-36	-160	-59	N/A
8/31/2020	236	-62	-154	-72	N/A
5/31/2020	213	-49	-146	-70	N/A
2/29/2020	197	-24	-115	-53	N/A
11/30/2019	173	-5	-73	-31	N/A
8/31/2019	135	1	-52	-16	N/A
5/31/2019	118	3	-59	-16	N/A
2/28/2019	97	4	-38	-2	N/A
11/30/2018	76	2	-34	-12	N/A
8/31/2018	61	1	-31	-12	N/A
5/31/2018	45	1	N/A	-6	N/A
2/28/2018	34	-2	N/A	-7	N/A
11/30/2017	27	-2	N/A	-8	N/A
8/31/2017	20	-1	N/A	-1	N/A
8/31/2016	6	-1	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLLK.Fは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: CLLK.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: CLLK.F今後 3 年以内に収益を上げることが予想されます。

収益対市場: CLLK.Fの収益 ( 8.3% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: CLLK.Fの収益 ( 8.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLLK.Fの自己資本利益率は、3年後には低くなると予測されています ( 1.4 %)。

BICO Group 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ), Annual General Meeting, May 08, 2025

BICO Group AB Announces Management Changes

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘